Trial continues after patient death: French heartmaker

March 4, 2014

French biomedical firm Carmat said Tuesday it would implant its experimental artificial heart into another three people, as planned, after the first recipient died.

In an email to AFP, the company said it was too soon to draw conclusions about the device's efficacy.

A 76-year-old recipient died over the weekend, 75 days after receiving the gadget, whose trials are being closely followed by French investors.

"It is premature to draw conclusions based on the outcomes from a single patient," said the the firm, whose stock was suspended at its own request on Tuesday.

"Carmat does not intend announcing the results of this trial until the implants and 30-day followup of all four intended four patients are complete."

The septuagenarian with terminal was one of four people, all with end-stage , selected for the experiment.

The trial would be considered a success if each of the four survive for at least a month.

Artificial hearts have been in use for many years as a temporary fix for patients with chronic heart problems.

Unlike these mostly synthetic pumps, the Carmat product aims to provide a longer-term solution—up to five years—to bridge the wait for a and enabling hospitalised patients to go back home and even resume work.

The device, a self-contained unit implanted in a patient's chest, is a mix of synthetic materials and animal tissue, and seeks to mimic the form and function of an actual human .

Nearly 100,000 people in Europe and the United States are in need of a , according to Carmat.

Explore further: FDA OKs HeartWare device for transplant patients

Related Stories

French firm starts human trials of artificial heart

December 20, 2013

French biomedical firm Carmat said on Friday it had begun the first human trial of its prototype artificial heart, which aims at overcoming shortages of organs available for transplant.

Recommended for you

Smoking leaves lasting marks on DNA, study finds

September 20, 2016

(HealthDay)—Smoking cigarettes can leave a lasting imprint on human DNA, altering more than 7,000 genes in ways that may contribute to the development of smoking-related diseases, a new study says.

Sleep disorders may influence heart disease risk factors

September 20, 2016

Sleep problems including sleeping too little or too long, may be linked to a variety of factors that may raise the risk for cardiovascular diseases, according to a new American Heart Association scientific statement published ...

Sleep troubles, heart troubles?

September 20, 2016

(HealthDay)—Sleep disorders—including too little or too much sleep—may contribute to heart disease risk factors, the American Heart Association said in its first statement on the risks of sleep problems.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.